Buprenorphine Induction in a Rural Maryland Detention Center During COVID-19: Implementation and Preliminary Outcomes of a Novel Telemedicine Treatment Program for Incarcerated Individuals With Opioid Use Disorder
AuthorBelcher, Annabelle M
Cole, Thomas O
Welsh, Christopher J
JournalFrontiers in Psychiatry
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractOver 10 million individuals pass through U.S. detention centers on an annual basis, with nearly two-thirds meeting criteria for drug dependence/abuse. Despite proven efficacy, treatment with medications for opioid use disorder (MOUD) is underutilized in jail settings-a gap that could be addressed using telemedicine. Here we describe a new program of telemedicine-based clinical provision of new/continuing buprenorphine treatment for individuals detained in a rural jail. Implementation objectives were completed between January and August 2020, and patient encounters were conducted between August 2020 and February 2021. We established (i) telemedicine hardware/software capability; (ii) a screening process; (iii) buprenorphine administration methods; (iv) necessary medical release procedures; (v) telemedicine encounter coordination and medication prescription procedures; and (vi) a research platform. Seven incarcerated patients have been treated, two of whom were referred from community treatment. Patients were mostly male (71%), non-Hispanic White (86%), and averaged 33 years old. All patients tested positive for an opioid upon intake and began/continued buprenorphine treatment in the jail. Average time to first MOUD appointment was 9 days and patients were maintained in treatment an average 21 days. Referrals for continuing community treatment were offered to all patients prior to discharge. We report successful implementation of telemedicine MOUD in a rural detention center, with treatment engagement and initiation occurring prior to the high-risk period of discharge. The fact that this program was launched during the height of the pandemic highlights the flexibility of telemedicine-based buprenorphine treatment. Challenges and obstacles to implementation of buprenorphine treatment in a correctional system are discussed.
Rights/TermsCopyright © 2021 Belcher, Coble, Cole, Welsh, Whitney and Weintraub.
medications for addiction treatment (MAT)
medications for opioid use disorder (MOUD)
opioid agonist therapy (OAT)
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17155
- Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
- Authors: Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R Jr, Lincoln T, Friedmann PD, MassJCOIN Research Group.
- Issue date: 2021 Sep
- COVID-19 and treating incarcerated populations for opioid use disorder.
- Authors: Donelan CJ, Hayes E, Potee RA, Schwartz L, Evans EA
- Issue date: 2021 May
- Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
- Authors: Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, Kattakuzhy S, Greenblatt A, Welsh C, Pappas A, Ross TL, Belcher AM
- Issue date: 2021 Aug 2
- Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
- Authors: Watson DP, Swartz JA, Robison-Taylor L, Mackesy-Amiti ME, Erwin K, Gastala N, Jimenez AD, Staton MD, Messmer S
- Issue date: 2021 Mar 31
- Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
- Authors: Flavin L, Tofighi B, Krawczyk N, Schatz D, McNeely J, Butner J
- Issue date: 2022 Jan-Feb 01